BelACT

BelACT is an investigational **enzyme biopharmaceutical** being developed by Pharmact Health for **familial hypercholesterolemia**, with particular relevance to severe genetically driven disease associated with accelerated atherosclerosis. Company materials describe it as a **genetically engineered hyaluronidase candidate** and an innovative enzyme drug with markedly enhanced specific activity versus comparator or previously known substances. The program is positioned as a precision biotechnological approach intended to **break down arterial deposits and reverse advanced vascular changes**, addressing plaque burden and arteriosclerotic pathology that current lipid-lowering therapies do not directly remove. Available public information indicates the project remains in the **preclinical to early regulatory preparation stage**, with animal studies completed or ongoing and regulatory approval steps initiated, but no confirmed human clinical phase publicly established.